10 Power Stocks Crushing Wall Street — 7 at All-Time Highs

2. Cytokinetics, Inc. (NASDAQ:CYTK)

Cytokinetics snapped a two-day losing streak on Tuesday, soaring 40.45 percent to close at $49.62 apiece as investors cheered promising results from its study of Aficamten, its drug candidate for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

In its presentation to the European Society of Cardiology Congress 2025 in Madrid, Spain over the weekend, Cytokinetics, Inc. (NASDAQ:CYTK) said it found that Aficamten helped oHCM patients exercise better than those who took Metoprolol, which actually dropped exercise abilities.

“The clinical difference in the two treatments is reinforced by the effect of Aficamten on the secondary endpoints. Compared to first-line standard-of-care metoprolol, treatment with Aficamten had a larger effect on measures of symptoms, functional class, and LVOT gradients,” said Fady Malik, executive vice president for research and development at Cytokinetics, Inc. (NASDAQ:CYTK).

Aficamten is an investigational drug candidate currently being reviewed by the US Food and Drug Administration. A decision is expected by December 26, 2025.